Drug therapy for the treatment of Langerhans cell histiocytosis

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 14, 2005, Pages 2435-2441

  McClain, Kenneth L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

2 chlorodeoxyadenosine; Antimetabolites; Cladribine; Cytokines; Cytosine arabinoside; Immunodeficiency; Langerhans cell histiocytosis; Mercaptopurine; Methotrexate; Prednisone; Thalidomide; Vinblastine; Vincristine

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; CD52 ANTIGEN; CLADRIBINE; COLONY STIMULATING FACTOR 1 ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; CYTOKINE; CYTOKINE ANTIBODY; DOXORUBICIN; EPITOPE; ETANERCEPT; ETOPOSIDE; MELATONIN; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD1A; PENTASTATIN; PREDNISONE; PURINE ANTAGONIST; RETINOIC ACID; STEROID; T6 ANTIGEN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CELL PROLIFERATION; CLINICAL PROTOCOL; DENDRITIC CELL; DRUG RESPONSE; EOSINOPHIL; HISTIOCYTOSIS X; HUMAN; LYMPHOCYTE; MACROPHAGE; REVIEW; SKIN;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES; BRAIN DISEASES; CELL PROLIFERATION; CLADRIBINE; CYTARABINE; DRUG THERAPY, COMBINATION; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES; PREDNISONE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; RISK FACTORS; THALIDOMIDE; VINBLASTINE;

EID: 28244441642     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.14.2435     Document Type: Review

References (38)

1. MCCLAIN KL: Histiocytic disorders. In: Cancer Treatment, 5th edn. Charles M Haskell (Ed.), W.B. Saunders Company, Orlando FL (2001):1236-1244.
2. VASSALLO R, RYU JH, COLBY TV, HARTMAN T, LIMPER AH: Pulmonary Langerhans' cell histiocytosis. New Engl. J. Med. (2000) 342(26):1969-1978.
3. PROSCH H, GROIS N, PRAYER D et al.: Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr. Blood Cancer (2004) 43(6): 594-599.
4. GROIS N, PROSCH H, LASSMANN H, PRAYER D: Central nervous system disease in Langerhans cell histiocytosis. In: Histiocytic Disorders of Children and Adults. Basic Science, Clinical Features, and Therapy. S Weitzman and RM Egeler (Eds). Cambridge University Press (2005):208-228.
5. MCCLAIN K, JIN H, GRESIK V, FAVARA B: Langerhans cell histiocytosis: lack of a viral etiology. Am. J. Hematol. (1994) 46:16-20.
6. GLOTZBECKER MP, CARPENTIERI DF, DORMANS JP: Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children. J. Pediatr. Orthop. (2004) 24:123-129.
7. LAMAN JD, LEENEN PJM, ANNELS NE, HOGENDOORN PCW, EGELER RM: Langerhans-cell histiocytosis 'insight into DC biology'. Trends Immunol. (2003) 24(4):190-196.
8. GEISSMANN F, LEPELLETIER Y, FRAITAG S et al.: Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood (2001) 97(5):1241-1248.
9. EGELER RM, FAVARA BE, VANMEURS M, LAMAN JD, CLAASSEN E: Differential in situ cytokine profiles of Langerhans-like cells and T cells in langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood (1999) 94(12):4195-4201.
10. MURAKAMI I, GOGUSEV J, FOURNET JC, GLORION C, JAUBERT F: Detection of molecular cytogenetic aberrations in Langerhans cell histiocytosis of bone. Hum. Pathol. (2002) 33(5):555-560.
11. DACIS S, TRUSKY C, BAKKER A, FINKELSTEIN SD, YOUSEM SA: Genotypic analysis of pulmonary Langerhans cell histiocytosis. Hum. Pathol. (2003) 34(12):1345-1349.
12. BHATIA S, NESBIT ME JR, EGELER RM, BUCKLEY J, MERTENS A, ROBISON LL: Epidemiologic study of Langerhans cell histiocytosis in children. J. Pediatr. (1997) 130(5):774-784.
13. GADNER H, HEITGER A, GROIS N, GATTERER-MENZ I, LADISCH S: Treatment strategy for disseminated Langerhans cell histiocytosis. Med. Pediatr. Oncol. (1994) 23:72-80.
14. GADNER H, GROIS N, ARICO M et al.: A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J. Pediatr. (2001) 138(5):728-734.
15. WEITZMAN S, WAYNE A, ARCECI R, LIPTON JM, WHITLOCK JA, DEROSSIE G: Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med. Pediatr. Oncol. (1999) 33:476-781.
16. EGELER RM, KRAKER JD, VOUTE PA: Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med. Pediatr. Oncol. (1993) 21:265-270.
17. MCCOWAGE GB, FRUSH DP, KURTZBERG J: Successful treatment of two children with Langerhans cell histiocytois with 2′-deoxycoformycin. J. Pediatr. Hematol. Oncol. (1996) 18(2):154-158.
18. MISERY L, LARBRE B, LYONNET S: Remission of Langerhans cell histiocytosis with thalidomide treatment. Clin. Exp. Dermatol. (1993) 18(5):487.
19. MONTERO AJ, DIAZ-MONTERO CM, MALPICA A, RAMIREZ PT, KAVANAGH JJ: Langerhans cell histiocytosis of the female genital tract: a literature review. Int. J. Gynecol. Cancer (2003) 13: 381-388.
20. SANDER CS, KAATZ M, ELSNER P: Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology (2004) 208(2):149-152.
21. MCCLAIN KL, KOZINETZ CA: A Phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr. Blood Cancer (in press).
22. GROIS N, POTSCHGER U, PROSCH H et al.: Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr. Blood Cancer (2005):[Epub ahead of print].
23. CREWS KR, GANDHI V, SRIVASTAVA DK et al.: Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J. Clin. Oncol. (2002) 20(20):4217-4224.
24. BERNARD F, THOMAS C, CHIRON R et al.: Association between 2-CdA and Ara-C as a rescue for pediatric patients with LCH, hematological dysfunction and failure to standard therapy. Proceedings of the Histiocyte Society 19th Annual Meeting. Philadelphia, (2003).
25. AKKARI V, DONADIEU J, PIGUET C et al.: Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytois and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Tansplanta. (2003) 31:1097-1103.
26. ROLLAND A, GUYON L, CAI Y-H, BANCHEREAU J, PALUCKA K, MCCLAIN KL: Increased blood myeloid dendritic cells and DC-poietins in Langerhans cell histiocytosis. J. Immunol. (2005) [Epublication ahead of print].
27. WOMER RB ANUNCIATO KR, CHEHRENAMA M: Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis. Med. Pediatr. Oncol. (1993) 25(1):70-73.
28. HOEGER PH, NANDURI VR, HARPER JI, ATHERTON DA, PRITCHARD J: Long term follow up of topical mustine treatment for cutaneous langerhans cell histiocytosis. Br. J. Dermatol. (2000) 142(3):401-412.
29. WEITZMAN S, ARCECI R, BRAIER et al.: Cladribine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of LCH-S-98. Proceedings of the Histiocyte Society 20th Annual Meeting. Stockholm, Sweden (2004).
30. STINE KC, SAYLORS RL, SACCENTE S, MCCLAIN KL, BECTON D: Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr. Blood Cancer (2004) 43(1):81-84.
31. IDBAIH A, DONADIEU J, BARTHEZ MA et al.: Retinoic acid therapy in 'degenerative-like' neuro-Langerhans cell histiocytosis: a prospective pilot study. Pediatr. Blood Cancer (2004) 43(1):55-58.
32. HENTER J-I, KARLEN J, CALMING U, BERNSTRAND C, ANDERSSON U, FADEEL B: Successful treatment of Langerhans'-cell histiocytosis with etanercept. N. Engl. J. Med. (2001) 345(21):1577.
33. BECHAN G, LEE D, THROSBY M, ARCECI R: Evaluation of humanized anti-CD1a monoclonal antibodies for therapy in Langerhans cell histiocytosis and other leukemias. Proceedings of the Histiocyte Society 20th Annual Meeting. Stockholm, Sweden (2004).
34. JORDAN M, MCCLAIN KL, YAN X, HICKS J, JAFFE R: Langerhans cells in Langerhans cell histiocytosis express CD 52 (Campath). Pediatr. Blood Cancer (2005) 44(3):251-255.
35. GROIS N, PRAYER D, PROSCH H, MINKOV M, POTSCHGER U, GADNER H: Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis. Pediatr. Blood Cancer. (2004) 43:59-65.
36. DONADIEU J, ROLON M-A, THOMAS C et al.: Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based study. J. Pediatr. (2004) 144(3):344-350.
37. OTTAVIANO F, FINLAY JL: Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with cladribine. J. Pediatr. Hematol/Oncol. (2003) 25(7):575-577.
38. BUCHLER T, CERVINEK L, BELOHLAVEK O et al.: Langerhans cell histiocytosis with central nervous system involvement: follow-up with FDG-PET during treatment with cladribine. Pediatr. Blood Cancer (2005) 44(3):286-288.